Bio­mea Fu­sion stock soars on ear­ly-stage di­a­betes da­ta

Red­wood City, CA-based Bio­mea Fu­sion saw about a 50% in­crease in its stock to­day af­ter re­veal­ing ear­ly da­ta for its co­va­lent menin in­hibitor, BMF-219, for the treat­ment of type 2 di­a­betes.

Da­ta from two co­horts en­rolled in the Phase II por­tion of its on­go­ing Phase I/II clin­i­cal study showed po­ten­tial for the in­hibitor to “re­lease the brakes” of “re­gen­er­a­tion, re­ac­ti­va­tion, and preser­va­tion” of be­ta cells, Bio­mea re­port­ed. Be­ta cells have to work hard­er in peo­ple with type 2 di­a­betes in or­der to pro­duce enough in­sulin to low­er blood sug­ar lev­els, lead­ing to the loss or weak­en­ing of the cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER